肌醇预防妊娠期糖尿病：相互矛盾的试验给临床医生何种启示？
本文对近期荟萃分析中肌醇预防妊娠期糖尿病的证据进行批判性评估。研究发现各试验在人群特征、治疗起始时间和补充方案等方面存在显著异质性，现有证据无法确定最佳目标人群、方案或时机。短期耐受性良好，但新生儿长期结局数据有限，需更大规模随机试验明确疗效与安全性。
要点
- 肌醇预防GDM的荟萃分析存在显著异质性，解读需谨慎。
- 各试验在人群、用药时机和方案上差异大，无法确定最优策略。
- 短期耐受性良好，但新生儿长期安全性数据有限。
核心结论
- 现有证据提示肌醇对预防妊娠期糖尿病可能有获益信号，但尚不能确定最佳目标人群、补充方案和治疗起始时间。
研究设计与样本
- 对已发表荟萃分析中的随机对照试验进行临床和方法学特征的批判性评估。
主要发现
- 试验人群特征差异显著，包括糖尿病家族史、既往GDM史及超重或肥胖患病率。
- 治疗起始时间（14周前或后）和补充方案各异。
- 短期耐受性一致良好，但新生儿长期结局罕见报告，安全性数据有限。
关键数值与推荐
- 荟萃分析报告肌醇补充与GDM风险降低相关，但主要结局存在显著异质性。
- 现有证据无法区分真实疗效差异与统计功效差异。
临床怎么用
- 临床医生应谨慎解读荟萃分析结果，考虑个体患者特征。
- 需更多高质量随机试验明确肌醇的适用人群、方案和时机。
局限性
- 研究层面分析无法区分真实疗效差异与其他研究特征。
- 长期新生儿结局和安全性数据不足。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
BACKGROUND: A recent meta-analysis reported that myo-inositol supplementation was associated with a reduced risk of gestational diabetes mellitus. However, the primary outcome showed substantial between-study heterogeneity, complicating the interpretation and clinical applicability of the evidence.
OBJECTIVE: To discuss why randomized trials may have produced different results and identify the information needed to guide future research and clinical interpretation.
STUDY DESIGN: We critically appraised the clinical and methodological characteristics of the randomized controlled trials included in the published meta-analysis to explore factors that may have contributed to their variability in results.
RESULTS: Substantial differences were found in population characteristics, including the prevalence of a family history of diabetes, previous gestational diabetes mellitus, and overweight or obesity. Trials also differed in the timing of treatment initiation (before or after the 14th week) and in their supplementation protocols. The available evidence does not allow conclusions regarding treatment effect modification, because study-level analyses cannot distinguish true differences in treatment effects from differences in statistical power or other study characteristics. Short-term tolerability has been consistently reported; however, long-term neonatal outcomes have rarely been reported, and safety data remain limited.
CONCLUSION: The recent meta-analysis provided a signal of benefit of myo-inositol for prevention of gestational diabetes mellitus. This clinical perspective identifies and discusses clinical and methodological differences that may have contributed to the variability in results across trials. However, the available evidence does not establish the optimal target population, supplementation protocol, or timing of treatment initiation. Adequately powered randomized trials focusing on short- and long-term neonatal outcomes are needed to better define the efficacy and safety of myo-inositol for the prevention of gestational diabetes mellitus.
引用
- American Journal of Obstetrics and Gynecology：Myo-inositol to prevent gestational diabetes: “What do conflicting trials tell clinicians?”
- Lecis, D'Anna, Garzon, et al. Myo-inositol to prevent gestational diabetes: "What do conflicting trials tell clinicians?". Am J Obstet Gynecol. 2026. PMID: 42864184. doi:10.1016/j.ajog.2026.09.007
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。